Excise tax increases on drug imports to India should have little impact on the current robust growth of the Indian pharmaceutical industry, according to a report by global analytics company Crisil. The firm projects a domestic growth rate year-over-year increase of 16% to 17% through 2014, coupled with export increases of 17%, as India increasingly taps into generics and manufacturing opportunities for bulk drugs.

Related Summaries